• Select Biosciences
  • Select Biosciences
  • Technology Networks
  • Opal Financial Group
  • Select Biosciences
  • Opal Financial Group

Stem Cells in Research & Drug Discovery Trends 2012

Date Published: December 2012
Format: PDF
Pages: 75
Publisher: HTStec
Product Code: jc09091315
Availability: In Stock
Price: $2,500.00
Qty:     - OR -   Add to Wish List
Add to Compare

Stem Cells in Research & Drug Discovery Trends 2012


• This market report summarizes the results of HTStec’s 2nd industry-wide global web-based benchmarking survey on stem cells in research and drug discovery carried out in November 2012.
• The study was initiated by HTStec as part of its ongoing tracking of emerging life science markets and to update its previous report (July 2011). The questionnaire was compiled to meet the needs and interests of the stem cell vendor community. The main objectives were to comprehensively document current end user opinions, practices, and preferences for the use of stem cells in life science research and drug discovery applications, and to understand future requirements.
• The survey looked at the following aspects of stem cells in research and drug discovery as practiced today (2012) and in some cases as predicted for the future (2014): current use of stem cells; use of stem cells for clinical applications; stages of the drug discovery and development process where stem cells are primarily used; % of all cell work done that involves stem cells; disease areas utilizing stem cells; species derivation of stem cells used; % of stem cell research done with different stem cell types; key objectives of using stem cells; different phenotypic assays or characterization methods performed using stem cells; main plate format and number of wells per typical phenotypic screen using stem cells; biggest challenges faced when using stem cells; obstacles to working with stem cells; barriers encountered or envisaged with respect to intellectual property around stem cells; if the lack of any stem cell types currently pose a major limitation to research; use of certain technologies or products for stem cell culture and reprogramming; opinion on lentiviral or non-integrating methods of induced pluripotent stem cell (iPSC) generation from a validation and safety point of view; views on transdifferentiation; cell lineages into which stem cells are being differentiated; annual budget for stem cell related spending and its component breakdown; most used commercial vendors/suppliers of different stem cell types; main criteria sought when purchasing stem cells; factors that most influence stem cell-related purchasing; iPSC preferences in sourcing and starting material; most wanted presentation and formats of iPSC when purchasing; level of interest in outsourcing stem cell-related activities; applications of stem cells most interested to outsource; most important factors when selecting a provider for stem cell related external services; views on technical expertise and training in stem cell work; most used sources of information gathering about new stem cell products and related services; and awareness of any unmet needs in the area of stem cells.
• The main questionnaire consisted of 25 multi-choice questions and 5 open-ended questions. In addition, there were 7 questions related solely to survey demographics.
• The survey collected 133 validated responses, of these 76% provided comprehensive input.
• Survey responses were geographically split: 38% North America, 29% Europe, 20% Asia (excluding Japan), 9% Rest of World, and 4% Japan.
• Survey respondents were drawn from persons or groups interested in and/or using stem cells in life science research and drug discovery applications.
• Respondents came from 47 University; 20 Research Institute; 19 Biotech Company; 16 Hospital/Clinic/ Medical School; 14 Large Pharma; 6 Medium-Small Pharma; 3 Government Lab; 3 Not-For-Profit Research Center; 3 Contract Research Organisation; and 2 Academic Screening Center.
• Most survey respondents had a senior job role or position which was in descending order: 26 professors/ assistant professors; 22 research scientists; 18 principal investigators; 18 senior scientists/researchers; 11 department heads; 10 post-docs; 9 other roles; 8 graduate/PhD students; 4 lab managers; 3 directors; 3 section/group leaders; and 1 vice president.
• Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was fully reanalyzed after sub-division into the following 5 survey groups: 1) Pharma; 2) Smaller Screening Labs; 3) University & Research Institute; 4) Europe; and 5) North America.
• The majority of respondents were currently using stem cells.
• The majority of respondents do not use stem cells for clinical applications.
• The stage in the drug discovery and development process most applying stem cells was basic research.
• The median % of all cell work undertaken today (2012) by respondents involving stem cells was 25%.
• Most respondents were applying stem cells research in the oncology/cancer disease area.
• The majority of respondent’s stem cells research was done with human-derived cells.
• The stem cell type respondents were making greatest use of was mesenchymal stem cells.
• The biggest expected increase in the future use of stem cell types was for iPSC.
• The key objective of most respondents stem cell work was basic research.

Executive Summary .................................. 2
Table of Contents ..................................... 4
Survey Methodology ................................. 5
Organisation & Response of Survey Participants........................... 6
Respondent’s Company or Organisational Origin ......................... 7
Respondent’s Geographic Origin .............................. 8
Country of Origin of European Respondents ............................ 9
Respondent’s Job Role ................................ 11
Respondents Currently Using Stem Cells ............................ 12
Use of Stem Cells for Clinical Applications ............................. 13
Stages of Drug Discovery & Development Process Using Stem Cells Today ................ 14
% of All Cell Work Done With Stem Cells ............................. 15
Disease Areas Utilizing Stem Cells in Drug Discovery Applications .................... 16
% Stem Cell Research Done With Cells Derived From Different Species .................. 17
% of Work Done With Different Stem Cell Types Today (2012) ....................... 18
% of Work Expected to be Done With Different Stem Cell Types in the Future (2014) ................ 19
Anticipated Change in Stem Cell Type Usage ......................... 20
Key Objectives of Respondent’s Stem Cell Research....................... 21
Summary of Survey Findings (1) ............................. 22
Phenotypic Assays/Characterization Methods Performed on Stem Cells .................... 23
Typical Size of Phenotypic Screens Performed on Stem Cells ..................... 25
Typical Plate Format Used for Phenotypic Screens on Stem Cells ................... 26
Anticipated Change in Plate Format Used for Phenotypic Screens ...................... 27
Biggest Challenges Faced When Using Stem Cells Today ........................ 28
Main Obstacles in Stem Cell Research ............................ 30
Barriers Encountered or Envisaged With IP Around Stem Cells Today ..................... 31
Lack of Stem Cells Types That Pose a Major Limitation on Research .................. 32
Use of Stem Culture & Reprogramming Technologies or Products ..................... 33
Opinion on Lentiviral or Non-Integrating Methods of iPSC Generation from Validation and Safety Points of View .... 34
Respondent’s Views on Transdifferentiation .......................... 36
Cell Lineages into Which Respondents are Differentiating Stem Cells .................... 37
Other Cell Lineages into Which Respondents are Differentiating Stem Cells .................. 38
Annual Budget for Stem Cell Research............................ 39
Breakdown of 2012 Stem Cell Research Budget ......................... 40
Stem Cells in Drug Discovery Market Estimate ........................... 41
Stem Cells in Drug Discovery Market Estimate Segmentation ..................... 42
Breakdown of Stem Cells in Drug Discovery Market Estimate ..................... 43
Summary of Survey Findings (2) ............................. 44
Preferred Suppliers of Embryonic Stem Cells .......................... 46
Preferred Suppliers of Induced Pluripotent Stem Cells........................ 48
Preferred Suppliers of Neuronal Stem Cells ............................ 50
Preferred Suppliers of Mesenchymal Stem Cells ......................... 52
Preferred Suppliers of Hematopoietic Stem Cells ........................ 54
Preferred Suppliers of Cancer or Tumor Initiating Stem Cells ..................... 56
Preferred Suppliers for All Stem Cell Types ............................ 58
Supplier Share of Stem Cells Types Used in Research & Drug Discovery .................... 60
Influence of Criteria on Purchasing of Stem Cells ........................... 61
Most Important Factors Affecting Purchasing of Stem Cells ....................... 62
Induced Pluripotent Stem Cell Preferences in Sourcing Cells & Starting Material ................ 63
Preferred Presentation & Formats of Induced Pluripotent Stem Cells When Purchased ............... 64
Level of Interest in Outsourcing Stem Cell Research....................... 66
Applications of Stem Cell Research Respondents Want To Outsource .................... 67
Most Important Factors When Selecting Vendor for Stem Cell Services .................. 68
Views on Technical Expertise & Training in Stem Cell Work ....................... 69
Most Useful Sources of Information on Stem Cells ......................... 71
Unmet Needs in Stem Cell Research ............................... 72
Summary of Survey Findings (3) ............................. 73